Population‐based Discovery and Ethnically Mixed Mendelian Randomization Validation Identifies Telmisartan as a Candidate Drug for Alzheimer’s Disease in African Americans

Elevated incidences of Alzheimer’s disease (AD) and disease progression may be associated with African American (AA)‐specific disease comorbidities, such as hypertension, diabetes, and chronic kidney disease. Treatments and management of these comorbidities — such as antihypertensive angiotensin‐II receptor blockers (ARBs) — may reduce risk of AD in AA people, while conferring additional beneficial effects on renal function and diabetes control.